COVID-19 vaccination prevents a more severe course and treatment with complement inhibitors reduce worsening hemolysis during the Omicron pandemic in patients with PNH: a single-center study

References

• Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2021;137(10):1–10. doi: 10.1182/blood.2019003812.
   PubMed Web of Science ®Google Scholar
• Hill A, DeZern AE, Kinoshita T, et al. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3(1):17028. doi: 10.1038/nrdp.2017.28.
   PubMedGoogle Scholar
• Luzzatto L. PNH phenotypes and their genesis. Br J Haematol. 2020;189(5):802–805. doi: 10.1111/bjh.16473.
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Fujita M. Biosynthesis of GPI-anchored proteins: special emphasis on GPI lipid remodeling. J Lipid Res. 2016;57(1):6–24. doi: 10.1194/jlr.R063313.
   PubMed Web of Science ®Google Scholar
• Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804–2811. doi: 10.1182/blood-2014-02-522128.
   PubMed Web of Science ®Google Scholar
• Röth A, Nishimura JI, Nagy Z, et al. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020;135(12):912–920. doi: 10.1182/blood.2019003399.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Röth A, Soret J, et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol. 2021;8(5):e344–e354. doi: 10.1016/S2352-3026(21)00028-4.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Marotta S, Ricci P, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157. doi: 10.3389/fimmu.2019.01157.
   PubMed Web of Science ®Google Scholar
• WHO. WHO coronavirus disease (COVID-19) dashboard. COVID 19 Special Issue 2020; 10; 2021 [cited 2021 March 1]. Available from: https://covid19.who.int/.
   Google Scholar
• Parker C, Omine M, Richards S, International PNH Interest Group., et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(12):3699–3709. doi: 10.1182/blood-2005-04-1717.
   PubMed Web of Science ®Google Scholar
• Sutherland DR, Keeney M, Illingworth A. Practical guidelines for the high-sensitivity detection and monitoring of paroxysmal nocturnal hemoglobinuria clones by flow cytometry. Cytometry B Clin Cytom. 2012;82(4):195–208. doi: 10.1002/cyto.b.21023.
   PubMed Web of Science ®Google Scholar
• Clinical management of COVID-19: living guideline. Geneva: World Health Organization; 2023.
   Google Scholar
• Yüce M, Filiztekin E, Özkaya KG. COVID-19 diagnosis -a review of current methods. Biosens Bioelectron. 2021;172:112752. doi: 10.1016/j.bios.2020.112752.
   PubMed Web of Science ®Google Scholar
• Baskin JL, Pui CH, Reiss U, et al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet. 2009;374(9684):159–169. doi: 10.1016/S0140-6736(09)60220-8.
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Peffault de Latour R, Rottinghaus ST, et al. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. 2021;106(1):230–237. doi: 10.3324/haematol.2019.236877.
   PubMed Web of Science ®Google Scholar
• Yenerel MN, Sicre de Fontbrune F, Piatek C, et al. Phase 3 study of subcutaneous versus intravenous ravulizumab in eculizumab-experienced adult patients with PNH: primary analysis and 1-year follow-up. Adv Ther. 2023;40(1):211–232. doi: 10.1007/s12325-022-02339-3.
   PubMed Web of Science ®Google Scholar
• Schrezenmeier H, Kulasekararaj A, Mitchell L, et al. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study. Ther Adv Hematol. 2020; 11:2040620720966137. doi: 10.1177/2040620720966137.
   Web of Science ®Google Scholar
• Otieno SB, Altahan A, Kaweeta F, et al. Severe hemolysis in a COVID-19 patient with paroxysmal nocturnal hemoglobinuria. Case Rep Hematol. 2021;2021:6619177. doi: 10.1155/2021/6619177.
   PubMed Web of Science ®Google Scholar
• Sokol J, Nehaj F, Mokan M, et al. COVID19 infection in a patient with paroxysmal nocturnal hemoglobinuria: a case report. Medicine. 2021;100(20):e25456. doi: 10.1097/MD.0000000000025456.
   PubMed Web of Science ®Google Scholar
• Genthon A, Chiarabini T, Baylac P, et al. Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy. Leuk Lymphoma. 2021;62(6):1502–1505. doi: 10.1080/10428194.2020.1869963.
   PubMed Web of Science ®Google Scholar
• Shino M, Iizuka H, Fukushima H, et al. COVID-19 development during the treatment of paroxysmal nocturnal hemoglobinuria. Rinsho Ketsueki. 2023;64(3):224–229.
   PubMedGoogle Scholar
• Kim MK, Lee B, Choi YY, et al. Clinical characteristic of 40 patients infected with the SARS-CoV-2 omicron variant in Korea. J Korean Med Sci. 2022;37(3):e31. doi: 10.3346/jkms.2022.37.e31.
   PubMed Web of Science ®Google Scholar
• Sha J, Meng C, Sun J, et al. Clinical and upper airway characteristics of 3715 patients with the omicron variant of SARS-Cov-2 in Changchun, China. J Infect Public Health. 2023;16(3):422–429. doi: 10.1016/j.jiph.2023.01.013.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.
   PubMed Web of Science ®Google Scholar
• Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943. doi: 10.1001/jamainternmed.2020.0994.
   PubMed Web of Science ®Google Scholar
• Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of covid-19 in New York City. N Engl J Med. 2020;382(24):2372–2374. doi: 10.1056/NEJMc2010419.
   PubMed Web of Science ®Google Scholar
• Fan Y, Li X, Zhang L, et al. SARS-CoV-2 omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022;7(1):141.
   PubMed Web of Science ®Google Scholar
• Kumar S, Thambiraja TS, Karuppanan K, et al. Omicron and Delta variant of SARS-CoV-2: a comparative computational study of spike protein. J Med Virol. 2022;94(4):1641–1649. doi: 10.1002/jmv.27526.
   PubMed Web of Science ®Google Scholar
• Tian D, Sun Y, Xu H, et al. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 omicron variant. J Med Virol. 2022;94(6):2376–2383. doi: 10.1002/jmv.27643.
   PubMed Web of Science ®Google Scholar
• Jassat W, Karim S, Mudara C. Clinical severity of covid-19 patients admitted to hospitals in Gauteng, South Africa during the omicron-dominant fourth wave. Preprint at SSRN. Available from: https://ssrn.com/abstract=3996320. 2021).
   Google Scholar
• Iuliano AD, Brunkard JM, Boehmer TK, et al. Trends in disease severity and health care utilization during the early omicron variant period compared with previous SARS-CoV-2 high transmission periods – United States, December 2020–January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):146–152. doi: 10.15585/mmwr.mm7104e4.
   PubMed Web of Science ®Google Scholar
• Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in Tshwane, South Africa. Int J Infect Dis. 2022;116:38–42. doi: 10.1016/j.ijid.2021.12.357.
   PubMed Web of Science ®Google Scholar
• Ulloa AC, Buchan SA, Daneman N, et al. Estimates of SARS-CoV-2 omicron variant severity in Ontario, Canada. JAMA. 2022;327(13):1286–1288. doi: 10.1001/jama.2022.2274.
   PubMed Web of Science ®Google Scholar
• Lu G, Zhang Y, Zhang H, et al. Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in shanghai omicron wave. Emerg Microbes Infect. 2022;11(1):2045–2054. doi: 10.1080/22221751.2022.2109517.
   PubMed Web of Science ®Google Scholar
• Tregoning JS, Flight KE, Higham SL, et al. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626–636. doi: 10.1038/s41577-021-00592-1.
   PubMed Web of Science ®Google Scholar
• Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72–74. doi: 10.1016/S0140-6736(20)32623-4.
   PubMed Web of Science ®Google Scholar
• Graña C, Ghosn L, Evrenoglou T, et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev. 2022;12(12):CD015477.
   PubMedGoogle Scholar
• Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–1423. doi: 10.1056/NEJMoa2101765.
   PubMed Web of Science ®Google Scholar
• Cesaro S, Ljungman P, Mikulska M, et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia. 2023;37(9):1933–1938. doi: 10.1038/s41375-022-01578-1.
   PubMed Web of Science ®Google Scholar
• Riccardi N, Falcone M, Yahav D. Vaccination for SARS-CoV-2 in hematological patients. Acta Haematol. 2022;145(3):257–266. doi: 10.1159/000523753.
   PubMed Web of Science ®Google Scholar
• Redjoul R, Le Bouter A, Beckerich F, et al. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients. Lancet. 2021;398(10297):298–299. doi: 10.1016/S0140-6736(21)01594-4.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Maeda K, Matsuda K, et al. Coronavirus disease 2019 (COVID-19) breakthrough infection and post-vaccination neutralizing antibodies among healthcare workers in a referral hospital in Tokyo: a case-control matching study. Clin Infect Dis. 2022;75(1):e683–e691. doi: 10.1093/cid/ciab1048.
   PubMed Web of Science ®Google Scholar
• Pike A, McKinley C, Forrest B, et al. COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria. Lancet Haematol. 2022;9(8):e553–e556. doi: 10.1016/S2352-3026(22)00183-1.
   PubMed Web of Science ®Google Scholar
• Jin P, Li J, Pan H, et al. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. Signal Transduct Target Ther. 2021;6(1):48. doi: 10.1038/s41392-021-00481-y.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211. doi: 10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423–4428. doi: 10.1016/j.vaccine.2021.05.063.
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184(2):476–488.e11. doi: 10.1016/j.cell.2020.12.015.
   PubMed Web of Science ®Google Scholar
• Lee ARYB, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632. doi: 10.1136/bmj-2021-068632.
   PubMedGoogle Scholar
• Mastellos DC, Pires da Silva BGP, Fonseca BAL, et al. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clin Immunol. 2020;220:108598. doi: 10.1016/j.clim.2020.108598.
   PubMed Web of Science ®Google Scholar
• Mastaglio S, Ruggeri A, Risitano AM, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020;215:108450. doi: 10.1016/j.clim.2020.108450.
   PubMed Web of Science ®Google Scholar
• Diurno F, Numis FG, Porta G, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040–4047.
   PubMed Web of Science ®Google Scholar
• Giudice V, Pagliano P, Vatrella A, et al. Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study. Front Pharmacol. 2020;11:857. doi: 10.3389/fphar.2020.00857.
   PubMed Web of Science ®Google Scholar
• Peffault de Latour R, Bergeron A, Lengline E, et al. Complement C5 inhibition in patients with COVID-19 – a promising target? Haematologica. 2020;105(12):2847–2850.
   PubMed Web of Science ®Google Scholar
• Yu J, Yuan X, Chen H, et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020;136(18):2080–2089. doi: 10.1182/blood.2020008248.
   PubMed Web of Science ®Google Scholar
• Pike A, Muus P, Munir T, et al. COVID-19 infection in patients on anti-complement therapy: the leeds national paroxysmal nocturnal haemoglobinuria service experience. Br J Haematol. 2020;191(1):e1–e4. doi: 10.1111/bjh.17097.
   PubMed Web of Science ®Google Scholar
• Schüller H, Klein F, Lübbert M, et al. Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report. Ann Hematol. 2021;100(3):841–842. doi: 10.1007/s00277-020-04318-6.
   PubMed Web of Science ®Google Scholar
• Cavallaro F, Pasquini MC, Giannotta JA, et al. Breakthrough haemolysis in paroxysmal nocturnal haemoglobinuria after COVID-19 infection and COVID vaccination: what is worse? Blood Transfus. 2022;20(5):437–440.
   PubMed Web of Science ®Google Scholar
• Borges L, Pithon-Curi TC, Curi R, et al. COVID-19 and neutrophils: the relationship between hyperinflammation and neutrophil extracellular traps. Mediators Inflamm. 2020;2020:8829674–8829677. doi: 10.1155/2020/8829674.
   PubMed Web of Science ®Google Scholar
• Liao D, Zhou F, Luo L, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol. 2020;7(9):e671–e678. doi: 10.1016/S2352-3026(20)30217-9.
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Lazana I, Large J, et al. Terminal complement inhibition dampens the inflammation during COVID-19. Br J Haematol. 2020;190(3):e141–e143. doi: 10.1111/bjh.16916.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028–1037. doi: 10.1056/NEJMoa2029073.
   PubMed Web of Science ®Google Scholar
• Jang JH, Wong L, Ko BS, et al. Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study. Blood Adv. 2022;6(15):4450–4460. doi: 10.1182/bloodadvances.2022006960.
   PubMed Web of Science ®Google Scholar